UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
When will regulator visit Kolon TissueGene for inspection?
by Lee Hye-seon
2019-05-02 14:09
Civic group files complaint against Kolon, regulator
by Jeong Sae-im
2019-04-30 14:59
FDA OKs Celltrion’s antibiotics generic
by Lee Han-soo
2019-04-30 11:22
Huons, Genexine to cooperate on biopharmaceuticals
by Lee Han-soo
2019-04-29 15:10
Techniques for biobetters get ever more advanced
by Jeong Sae-im
2019-04-29 11:48
라인
Prosecutors seek arrest warrant of Samsung Bioepis executives
by Lee Han-soo
2019-04-26 17:19
FDA OKs Samsung Bioepis’ Etanercept biosimilar
by Lee Han-soo
2019-04-26 14:22
Foreign patients to join class-action suit against Kolon for Invossa
by Jeong Sae-im
2019-04-25 15:39
Samsung Bioepis’ biosimilar sales in EU topped $170 million in Q1
by Lee Han-soo
2019-04-25 14:07
Samsung Biologics logs ₩23.4 billion operating loss in Q1
by Jeong Sae-im
2019-04-25 12:08
라인
OECD guideline OKs Korean-developed eye irritation test
by Lee Hye-seon
2019-04-22 15:33
Gene therapies’ potentials, challenges explained
by Jeong Sae-im
2019-04-22 11:46
Why is TissueGene CEO silent about Invossa mislabeling?
by Jeong Sae-im
2019-04-19 14:37
‘How Korean pharma companies can succeed in US’
by Lee Han-soo
2019-04-18 14:41
Kolon desperate to keep Invossa license amid suspicion of data fabrication
by Lee Hye-seon
2019-04-18 11:16
라인
Patients to file class-action suit against Kolon over Invossa
by Jeong Sae-im
2019-04-17 14:58
‘Invossa lacked clinical evidence to be commercialized’
by Jeong Sae-im
2019-04-17 12:45
BIO KOREA 2019 aims to lead open innovation
by Lee Han-soo
2019-04-17 12:42
Celltrion unveils P2 trial results for influenza antibody therapy
by Lee Han-soo
2019-04-16 16:16
‘Kolon might have fabricated data to get Invossa approval’
by Jeong Sae-im
2019-04-16 11:07
-
이전
11
12
13
14
15
16
17
18
19
20
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top